well as patients with a history of previous vascular decompression and/or TNA blocks were excluded. Demographic characteristics, operative details, and perioperative pain treatment data were collected. Primary end points included postoperative pain relief, levels of carbamazepine, facial numbness, and complications. Continuous and categorical data were analyzed with the Wilcoxon rank sum test, Pearson’s x 2 test, or Fisher exact test, as appropriate. RESULTS: Radiosurgery and balloon compression groups contained 59 and 62 patients, respectively. Balloon compression had a lower mean postoperative pain control (36.7% vs 19%; P ¼ .0281) and mean calculated pain control in VAS scale at 2 weeks (47.3% vs 22.65%; P ¼ .0236), this did not translate to a statistically significant difference in mean pain control at 3 months (68.7% vs 83.93% P ¼ .137), 18 months (57.8% vs 73.93% P ¼ .098), and carbamazepine usage after 3 months (balloon compression [31.9%] vs GKRS [37.7%]; P ¼ .71). Most common side effects were facial numbness postoperative v2, v3 distribution (64.23% vs 13.12%; P ¼ .00192) and 3 months (24.68% vs 17.29%; P ¼ .034). CONCLUSION: Balloon compression decreased acute primary tri- geminal neuralgia, but did not provide a clinically substantial advantage compared with GKRS in terms of decreasing pharmacological dosage and pain relief in a 24-month period. 105 Incidence and Predictors of Complications After Bypass Surgery for Pediatric Patients With Moyamoya Disease Yimo Lin, BA; Dominic Harris, I-Wen Pan, PhD; Thomas G. Luerssen, BS, MD, FACS, FAAP; Sandi Lam, MD, MBA INTRODUCTION: Moyamoya is a rare disease, and thus there have been few published studies with sufficient power for outcomes analyses of bypass surgery performed in the modern era. METHODS: This Kids Inpatient Database (KID) was queried for hospitalizations of pediatric patients with Moyamoya disease undergoing extracranial-intracranial vascular bypass surgery in the years 2003, 2006, and 2009. Type of bypass (direct vs indirect) was not distinguishable in coding. Multivariate logistic regression was conducted to identify covariates associated with in-hospital complications. RESULTS: An estimated total of 477 hospitalizations for bypass surgery were identified in the years of the study. The mean age was 9.5 years. The incidence of Down syndrome in the cohort was 7%, the incidence of sickle cell hemoglobinopathy was 12.1%, the incidence of neurofibromatosis type 1 was 5.9%, and the incidence of preexisting neurological deficit was 21%. The incidence of in-hospital complications were as follows: postoperative stroke 1%, subdural hematoma 0.4%, death 0.4%, seizures 12.2%, wound infection 1%, meningitis 0.4%, sepsis 0.4%, CSF leak 0.7%. There were no cases of cardiopulmonary collapse or deep vein thrombosis/pulmonary embolism. In a multivariate regression model controlling for demographics, hospital, and clinical factors, longer length of stay (OR, 1.12; P ¼ .027), increased number of procedures done during hospitalization (OR, 2.2; P ¼ .04), and the presence of 1 of 4 comorbidities (Down syndrome, NF1, sickle cell, preexisting neurological deficit) (OR, 2.3; P ¼ .034) were significantly associated with increased risk of complications. Age, sex, race, hospital type or location, and hospital volume were not significantly associated with outcomes. CONCLUSION: Increased length of stay, increased number of procedures done in-hospital, and the presence of certain comor- bidities were associated with a higher incidence of complications among pediatric patients undergoing bypass surgery for Moyamoya disease. 106 Functional Network Analysis in Surgical Epilepsy Patients Using Magnetoencephalography Dario J. Englot, MD, PhD; Robert C. Knowlton, MD; Edward F. Chang, MD; Heidi E. Kirsch, Srikantan S. Nagarajan, PhD INTRODUCTION: Intractable focal epilepsy is a devastating disorder with profound effects on cognition and quality of life. Epilepsy surgery can lead to seizure freedom in patients with focal epilepsy; however, sometimes it fails owing to an incomplete delineation of the epileptogenic zone (EZ). Brain networks in epilepsy can be studied with resting-state functional connectivity (RSFC) analysis, yet previous investigations using functional MRI or electrocorticography have produced inconsistent results. Magnetoencephalography (MEG) allows noninvasive whole- brain recordings, and can be used to study both long-range network disturbances in focal epilepsy and regional connectivity at the EZ. METHODS: In MEG recordings from presurgical epilepsy patients, we examined: (1) global functional connectivity maps in patients vs controls, and (2) regional functional connectivity maps at the region of resection, compared with the homotopic nonepileptogenic region in the contralateral hemisphere. RESULTS: Sixty-one patients were studied, including 30 with mesial temporal lobe epilepsy and 31 with focal neocortical epilepsy. Compared with a group of 31 controls, epilepsy patients had decreased RSFC in widespread regions, including perisylvian, posterior temporoparietal, and orbitofrontal cortices (P , .01, false discovery rate-corrected). Decreased mean global connectivity was related to longer duration of epilepsy and higher frequency of consciousness-impairing seizures (P , .01, linear regression). Furthermore, patients with increased regional connectivity within the resection site (n ¼ 24) were more likely to achieve postoperative seizure freedom (87.5% with Engel I outcome) than those with neutral (n ¼ 15, 64.3% seizure free) or decreased (n ¼ 23, 47.8% seizure free) regional connectivity (P , .02, x 2 ). CONCLUSION: Widespread global decreases in functional connec- tivity are observed in patients with focal epilepsy and may reflect deleterious long-term effects of recurrent seizures. Furthermore, enhanced regional functional connectivity at the area of resection may help predict seizure outcome and aid surgical planning. 107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma David A. Reardon, MD; James M. Schuster, MD; David Dinh Tran, Karen L. Fink, MD, PhD; Louis B. Nabors, MD; Gordon Li, MD; Daniela Annenelie Bota, MD; Rimas Vincas Lukas, MD; Annick Desjardins, MD, FRCP; Lynn Stuart Ashby, J. Paul Duic, Maciej M. Mrugala, MD, PhD, MPH; Andrea Werner, Thomas Hawthorne, Yi He, Jennifer Green, Michael Jay Yellin, Christopher D. Turner, Thomas A. Davis, John H. Sampson, MD, PhD, MHSc, MBA INTRODUCTION: EGFRvIII, a constitutively active EGFR deletion driver mutation, is associated with poor long-term survival in glioblastoma CNS ORAL PRESENTATIONS 198 | VOLUME 62 | NUMBER 1 | AUGUST 2015 www.neurosurgery-online.com Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited